Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01786811 · ClinicalTrials.gov registry record · NA

Serious Illness Communication Project

A NA study of Cancer and End of Life Care, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
994
Enrollment target
1
Study location

NCT01786811: Completed NA study of Cancer and End of Life Care, sponsored by Dana-Farber Cancer Institute.

NCT01786811 is a NA study of Cancer and End of Life Care that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 994 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01786811, a NA study of Cancer and End of Life Care, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
994 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to evaluate the impact of implementing a "Serious Illness Conversation Guide" to guide patient/family-clinician discussions and planning about end-of-life care decisions. The goal of the intervention is to improve achievement of patient care priorities and peacefulness at the end of life for patients with serious and life-threatening illness and their families. We hypothesize that patients whose physician is trained to use and adheres to the elements of the Serious Illness Conversation Guide will demonstrate enhanced consistency between documented key priorities and care received, and will experience greater peace in the final month of life; similarly, their families will experience higher satisfaction with care.

Primary Outcome

Patients whose physician is trained to use and adheres to the SICG will receive care that is more consistent with their key life priorities during the last week and the last 3 months of life than patients whose physician is not trained to use the SICG. Goal consistent care will be measured by comparing goals identified by the patient during the final 3 months and final week of life, to care received by the patient, which will be measured by chart review and family report. For each priority/goal

Conditions Studied

Interventions

  • BEHAVIORAL Training

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 994 participants
Start Date 2012-06
Est. Completion 2016-06
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the finished NCT01786811 record still lists

NCT01786811 is an interventional study that assigns participants to a tested intervention. The registered 994 participants enrollment target is mid-sized for trials with a published cap, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (72% lower).

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Training is the first listed.

NCT01786811 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01786811 about?

NCT01786811 is a clinical study titled "Serious Illness Communication Project". The purpose of the study is to evaluate the impact of implementing a "Serious Illness Conversation Guide" to guide patient/family-clinician discussions and planning about end-of-life care decisions. The goal of the intervention is to improve achievement of patient care priorities and peacefulness at...

What is the current status of trial NCT01786811?

This trial is currently completed. It is a NA study. The enrollment target is 994 participants. The study started on 2012-06. Estimated completion is 2016-06.

What conditions does trial NCT01786811 study?

This clinical trial studies the following conditions: Cancer, End of Life Care.

What interventions are being tested in trial NCT01786811?

The interventions under investigation include: Training (BEHAVIORAL).

Who is sponsoring clinical trial NCT01786811?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01786811 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01786811's enrollment target sits among peer trials

994 87th of 615 higher than 528 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05437575 · 994 participants · Phase 3

    Prehospital Analgesia INtervention Trial (PAIN)

  • NCT05987241 · 992 participants · Phase 2

    Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  • NCT05441709 · 990 participants · NA

    Furthering Equity Through Infant Feeding EDucation and Support

  • NCT06340646 · 990 participants · NA

    Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01786811, the US trial registry maintained by the National Library of Medicine. NCT01786811 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.